The Southeast Clinical Oncology Research Consortium (SCOR) is a unique organization comprised of 21 community members from rural and metropolitan areas under the leadership of three experienced Principal Investigators (PIs), a Leadership Council, and the SCOR Operations Center (SOC). The members comprise small community hospitals, hospital systems, and private practices in a six-state geographical area (Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia). The primary goal of this application is to bring NCI clinical trials and Cancer Care Delivery Research (CCDR) to the catchment area. A second goal is to facilitate the use of effective, evidence-based practices to improve the quality of care, health outcomes, and reduce cancer health care disparities. There are currently 230 investigators and 160 clinical research staff across 93 treatment performance sites engaged in National Cancer Institute (NCI) research. Each community has a Community Responsible Investigator to oversee research and to ensure human subjects protection. SCOR has a Young Investigator Mentoring Program designed to increase participation of the next generation of NCI investigators in cancer clinical research. Each community also has a research coordinator who is responsible for clinical operations. The SCOR catchment area includes over 16 million people with significant ethnic, rural, and medically underserved populations. The SOC in Winston-Salem, NC provides extensive expertise, regulatory assistance, training, monitoring, mentoring, education, and coordination to facilitate member community?s ability to provide clinical trials to their patient population. SOC staff conducts at least yearly site visits to each community member to review their research program and recruitment strategies, to ensure compliance and quality data submission, and to assist with audit preparation. This infrastructure allows understaffed member communities to conduct NCI clinical research. The efficient, centralized SOC and experienced PI leadership will facilitate accomplishment of the goals of this application.

Public Health Relevance

Advances in oncology are made through the execution of well-designed innovative clinical trials, including participation in Cancer Care Delivery Research, and these advances will lead to improved quality of life and health outcomes, as well as reducing cancer health disparities. This 21-community organization has the expertise, strength, capacity, and capability to contribute to these outcomes. Through covering a six-state area, this organization provides clinical trial access to small, rural, medically underserved, and Appalachia communities of the Southeast.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189858-06
Application #
9769929
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Parker, Bernard W
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2019-08-21
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Southeast Clinical Oncol Research Consortium
Department
Type
DUNS #
876940532
City
Winston-Salem
State
NC
Country
United States
Zip Code
27104
Guercio, Brendan J; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One 13:e0199244
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Gajra, Ajeet; McCall, Linda; Muss, Hyman B et al. (2018) The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). J Geriatr Oncol 9:221-227
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528

Showing the most recent 10 out of 36 publications